JP2008505087A5 - - Google Patents

Download PDF

Info

Publication number
JP2008505087A5
JP2008505087A5 JP2007519344A JP2007519344A JP2008505087A5 JP 2008505087 A5 JP2008505087 A5 JP 2008505087A5 JP 2007519344 A JP2007519344 A JP 2007519344A JP 2007519344 A JP2007519344 A JP 2007519344A JP 2008505087 A5 JP2008505087 A5 JP 2008505087A5
Authority
JP
Japan
Prior art keywords
glucagon
insulin
amount
milliunits
units
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007519344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505087A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/022812 external-priority patent/WO2006004696A2/en
Publication of JP2008505087A publication Critical patent/JP2008505087A/ja
Publication of JP2008505087A5 publication Critical patent/JP2008505087A5/ja
Pending legal-status Critical Current

Links

JP2007519344A 2004-06-29 2005-06-27 インスリン誘発性低血糖の予防および制御のための組成物ならびに方法 Pending JP2008505087A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58444904P 2004-06-29 2004-06-29
PCT/US2005/022812 WO2006004696A2 (en) 2004-06-29 2005-06-27 Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Publications (2)

Publication Number Publication Date
JP2008505087A JP2008505087A (ja) 2008-02-21
JP2008505087A5 true JP2008505087A5 (enExample) 2008-07-31

Family

ID=35783298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007519344A Pending JP2008505087A (ja) 2004-06-29 2005-06-27 インスリン誘発性低血糖の予防および制御のための組成物ならびに方法

Country Status (11)

Country Link
EP (1) EP1778266A4 (enExample)
JP (1) JP2008505087A (enExample)
KR (1) KR20070029276A (enExample)
CN (1) CN101001638A (enExample)
AU (1) AU2005260025A1 (enExample)
CA (1) CA2571030A1 (enExample)
IL (1) IL180361A0 (enExample)
MX (1) MXPA06014970A (enExample)
NO (1) NO20070174L (enExample)
WO (1) WO2006004696A2 (enExample)
ZA (1) ZA200700708B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2635296B1 (en) 2010-11-03 2014-12-24 Arecor Limited Novel composition comprising glucagon
CA2995392C (en) 2015-09-04 2023-08-15 Hailiang Chen Stabilized glucagon solutions
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
ES2944544T3 (es) * 2017-02-03 2023-06-22 Univ Vanderbilt Sistemas, composiciones y métodos para el tratamiento de la diabetes
MX2020000514A (es) * 2017-07-14 2020-08-03 Xeris Pharmaceuticals Inc Metodos para tratar el hiperinsulinismo congenito.
WO2019108640A1 (en) * 2017-11-28 2019-06-06 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods and kits for evaluating metabolism
KR20230026984A (ko) * 2020-06-26 2023-02-27 엑스에리스 파머수티클스, 인크. 비양성자성의 극성 용매 중의 안정한 지속 방출성 치료 조성물 및 그의 제조 방법
GB202109087D0 (en) * 2021-06-24 2021-08-11 Norwegian Univ Sci & Tech Ntnu Therapeutic methods and devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897551A (en) * 1971-04-05 1975-07-29 Lilly Co Eli Iodoglucagons and process for prolonging the biological activity of glucagon
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
AU2003274601A1 (en) * 2002-11-18 2004-06-15 Pfizer Products Inc. Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
NZ541365A (en) * 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Similar Documents

Publication Publication Date Title
US20260034221A1 (en) Buffered formulations of exendin (9-39)
Whitehead et al. Oral delivery of macromolecules using intestinal patches: applications for insulin delivery
AU2015204491B2 (en) Rapid action insulin formulations and pharmaceutical delivery systems
JP2020033360A5 (enExample)
JP2021503468A5 (enExample)
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
JP2005501110A5 (enExample)
JP2019517542A5 (enExample)
JP2018138578A5 (enExample)
JP2005520778A5 (enExample)
HRP20150186T1 (hr) Eksendin za lijeäśenje dijabetesa i smanjenje tjelesne težine
HK1203371A1 (en) Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
JP2013522194A5 (enExample)
ES2922551T3 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
MXPA05006994A (es) Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
CA2971440A1 (en) Method and compositions for dissolving or solubilizing therapeutic agents
JP2018509419A5 (enExample)
JP2010516671A (ja) 糖尿病の治療のためのエクセナチド及びダラルギンに基づく医薬、その使用及び治療方法
ES3062720T3 (en) Sublingual epinephrine tablets
Becker et al. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes
CN114423461B (zh) 组合
Bush Intensive diabetes therapy and body weight: focus on insulin detemir
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
Mannucci et al. Back to glycemic control: an alternative look at the results of cardiovascular outcome trials in type 2 diabetes
CZ389498A3 (cs) Lokální anestetikum s pufrovaným složením pro zabránění vzniku zánětu